STAT

Opinion: The medical community is changing its mind on chronic fatigue syndrome. Why aren’t insurers?

It's time to stop denying disability benefits for people with chronic fatigue syndrome.
NIH Director Francis Collins and Brian Vastag in 2017. The NIH launched a study seeking answers on chronic fatigue syndrome after Vastag wrote an open letter to Collins in 2015.

Brian Vastag was enjoying a life that many people would envy. At age 41, he had achieved professional success as an award-winning health and science reporter for the Washington Post, covering important stories from around the world. That came to an end in July 2012, when he found himself afflicted by a mysterious and poorly understood illness that ended up sweeping away almost every vestige of his vigorous and productive life. To add insult to injury, he also had to endure a four-year battle with his insurance company to cover his disability claim for the condition he eventually learned was chronic fatigue syndrome.

Like many Americans who experience serious health setbacks, Vastag thought he could rely for help on the disability, often abbreviated as ME/CFS), many of the 1 million or more Americans who have it are ridiculed and dismissed as delusional, hysterical, or suffering from some psychiatric disorder.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Doctors Powering Telehealth GLP-1 Scripts, An FDA Hold On A Novavax Shot, And More
A handful of clinician networks write prescriptions for dozens of websites offering the GLP-1 weight loss drugs
STAT1 min read
STAT+: With A Win In Lung Cancer, Biotech’s Wealthiest Outsider Surfs To New Heights
Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in biotech.
STAT1 min read
Opinion: STAT+: Eli Lilly Chief Scientist Daniel M. Skovronsky: Beware Elected Leaders Who Would Weaken Patents
“Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and look for policies to weaken them,” writes Eli Lilly’s Daniel…

Related